Suppr超能文献

含纯生长因子的B.P.F.C.®生物血浆(BioPlasma®)用于治疗根管治疗后患牙的持续性根尖周大病变:一种新的治疗选择。

B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) Used for the Treatment of a Persistent Great Periapical Lesion of an Endodontically Treated Tooth: A New Therapeutic Option.

作者信息

Viganò Raffaello, Disconzi Mirko, Bertini Edoardo, Viganò Luca, Casu Cinzia

机构信息

DDS, Freelancer in Varese, Italy.

University of Milano, Milano, Italy.

出版信息

Case Rep Dent. 2020 Jun 29;2020:4876437. doi: 10.1155/2020/4876437. eCollection 2020.

Abstract

The aim of this case report was to evaluate the efficacy of a new platelet-rich plasma preparation and its regenerative capacity of bone periapical tissue for the treatment of a very compromised endodontic treated tooth, with a periapical lesion of 1.5 cm in diameter, using a pure platelet concentrate. This is made without the use of anticoagulant or any type of activator, e.g., bovine thrombin, calcium chloride. For this reason, it has been called "Pure"; it is the B.P.F.C.® Bio-Plasma® with Pure Growth Factors (BioPlasma®) designed and developed by Dr. Raffaello Viganò. The patient has read and signed a written consent form. The study protocol was approved by the Ethics Committee for Human Studies, University of Varese. X-ray at 2 and 6 months and 4 years after endodontic surgery demonstrated the success of the treatment.

摘要

本病例报告的目的是评估一种新型富血小板血浆制剂的疗效及其对根尖周组织的再生能力,该制剂为纯血小板浓缩物,用于治疗一颗根管治疗后严重受损且根尖周病变直径达1.5厘米的牙齿。该制剂的制备不使用抗凝剂或任何类型的激活剂,如牛凝血酶、氯化钙。因此,它被称为“纯”;它是由拉斐尔洛·维加诺博士设计和研发的含有纯生长因子的B.P.F.C.®生物血浆®(BioPlasma®)。患者已阅读并签署了书面知情同意书。该研究方案已获得瓦雷泽大学人体研究伦理委员会的批准。根管治疗术后2个月、6个月和4年的X线检查显示治疗成功。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ce0/7341431/ad734ee0f82e/CRID2020-4876437.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验